AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Update

AngioDynamics, Inc. (NASDAQ:ANGO) was the recipient of a large decrease in short interest in December. As of December 15th, there was short interest totalling 1,000,000 shares, a decrease of 12.3% from the November 30th total of 1,140,000 shares. Based on an average daily volume of 582,000 shares, the days-to-cover ratio is currently 1.7 days.

AngioDynamics Stock Up 1.6 %

ANGO opened at $9.05 on Tuesday. AngioDynamics has a fifty-two week low of $5.26 and a fifty-two week high of $9.58. The firm has a market cap of $367.74 million, a PE ratio of -1.49 and a beta of 0.68. The business has a fifty day simple moving average of $7.61 and a 200-day simple moving average of $7.16.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04. The firm had revenue of $67.50 million for the quarter, compared to analysts’ expectations of $67.93 million. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The company’s quarterly revenue was down 14.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.12) EPS. On average, equities research analysts anticipate that AngioDynamics will post -0.41 EPS for the current fiscal year.

Insider Buying and Selling

In other AngioDynamics news, CEO James C. Clemmer acquired 20,000 shares of the stock in a transaction on Monday, October 7th. The stock was purchased at an average price of $6.03 per share, for a total transaction of $120,600.00. Following the purchase, the chief executive officer now directly owns 681,582 shares in the company, valued at $4,109,939.46. This trade represents a 3.02 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders acquired 22,568 shares of company stock valued at $135,847. 5.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp lifted its stake in AngioDynamics by 9.7% in the second quarter. Bank of New York Mellon Corp now owns 174,742 shares of the medical instruments supplier’s stock valued at $1,057,000 after acquiring an additional 15,412 shares during the last quarter. Concurrent Investment Advisors LLC grew its holdings in shares of AngioDynamics by 152.2% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 29,503 shares of the medical instruments supplier’s stock worth $178,000 after purchasing an additional 17,803 shares in the last quarter. First Eagle Investment Management LLC acquired a new stake in AngioDynamics during the second quarter valued at approximately $1,321,000. AE Wealth Management LLC acquired a new stake in AngioDynamics in the 2nd quarter valued at $87,000. Finally, Cubist Systematic Strategies LLC lifted its holdings in AngioDynamics by 15.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 226,503 shares of the medical instruments supplier’s stock valued at $1,370,000 after purchasing an additional 29,669 shares during the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Canaccord Genuity Group reduced their price objective on AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, October 4th. HC Wainwright reiterated a “buy” rating and set a $14.00 price objective on shares of AngioDynamics in a research note on Tuesday, December 10th.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.